As global markets navigate a landscape marked by dovish Federal Reserve signals and mixed economic indicators, investors are observing notable movements in indices such as the Nasdaq Composite and Russell 2000. In this dynamic environment, dividend stocks offer a compelling opportunity for those seeking steady income streams amidst fluctuating market conditions.
|
Name |
Dividend Yield |
Dividend Rating |
|
Yeni Gimat Gayrimenkul Yatirim Ortakligi (IBSE:YGGYO) |
5.47% |
★★★★★★ |
|
Yamato Kogyo (TSE:5444) |
3.91% |
★★★★★★ |
|
Torigoe (TSE:2009) |
3.97% |
★★★★★★ |
|
Telekom Austria (WBAG:TKA) |
4.65% |
★★★★★★ |
|
NCD (TSE:4783) |
4.45% |
★★★★★★ |
|
Kyoritsu Electric (TSE:6874) |
3.72% |
★★★★★★ |
|
Guangxi LiuYao Group (SHSE:603368) |
4.08% |
★★★★★★ |
|
GakkyushaLtd (TSE:9769) |
4.60% |
★★★★★★ |
|
Business Brain Showa-Ota (TSE:9658) |
3.79% |
★★★★★★ |
|
Binggrae (KOSE:A005180) |
4.45% |
★★★★★★ |
Click here to see the full list of 1318 stocks from our Top Global Dividend Stocks screener.
Let’s review some notable picks from our screened stocks.
Simply Wall St Dividend Rating: ★★★★★☆
Overview: Shandong Nanshan Aluminium Co., Ltd. engages in aluminum processing activities globally and has a market cap of CN¥56.63 billion.
Operations: Shandong Nanshan Aluminium Co., Ltd. generates revenue through its global aluminum processing operations.
Dividend Yield: 3.2%
Shandong Nanshan Aluminium Ltd. offers a mixed picture for dividend investors. While its dividend yield of 3.19% ranks in the top 25% of CN market payers, the company’s dividends have been volatile over the past decade, lacking consistency in growth. However, dividends are well-covered by earnings and cash flows with payout ratios of 29.6% and 40.8%, respectively, suggesting sustainability despite historical unreliability. Recent earnings show a net income increase to CNY 3.77 billion for nine months ending September 2025, indicating potential financial stability moving forward.
Simply Wall St Dividend Rating: ★★★★★★
Overview: Luyan Pharma Co., Ltd. is involved in the research, development, production, and sale of pharmaceutical products in China with a market cap of CN¥3.95 billion.
Operations: Luyan Pharma Co., Ltd. generates its revenue through the research, development, production, and sale of pharmaceutical products within China.
Dividend Yield: 3.2%
Luyan Pharma Ltd. provides a reliable dividend profile, with a stable and growing dividend history over the past decade. The company’s dividends are well-covered by earnings and cash flows, reflected in payout ratios of 43.8% and 40.3%, respectively, ensuring sustainability. Despite recent earnings showing a decline in net income to CNY 219.67 million for the nine months ending September 2025, its dividend yield at 3.22% remains attractive within the top quartile of CN market payers.
